Home > Riviste > Minerva Pediatrics > Fascicoli precedenti > Articles online first > Minerva Pediatrics 2022 Aug 01

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

Review Article   

Minerva Pediatrics 2022 Aug 01

DOI: 10.23736/S2724-5276.22.06968-3

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

Biotics in neonatal period: what’s the evidence?

Flavia INDRIO 1 , Flavia MARCHESE 1, Isadora BEGHETTI 2, Massimo PETTOELLO MANTOVANI 1, Assunta GRILLO 1, Arianna ACETI 2

1 Pediatric Section, Department of Medical and Surgical Science, University of Foggia, Foggia, Italy; 2 Neonatal Intensive Care Unit, Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy


PDF


INTRODUCTION: Breastfeeding is considered the gold standard for infants’ nutrition and provides unique benefits for infants’ health.
EVIDENCE ACQUISITION: Great research interest has been raised about the use of bioactive components in neonatal medicine, both as standalone products and as addition to infant formula, in the attempt to reproduce human milk beneficial effects. Thus, the aim of this narrative review is to summarize most recent evidence on biotics’ use in the neonatal period, with a focus on infant formula (IF) supplemented with probiotics, prebiotics, synbiotics and postbiotics.
EVIDENCE SYNTHESIS: Growing data indicate overall positive effects of biotic supplemented formula on microbiome composition and metabolic activity. Furthermore, some benefits are also emerging from randomized controlled trials (RCTs) evaluating the clinical impact these enriched formulas may have on the health of formula fed infants. However, clear evidence still lacks and none of this supplemented IF has demonstrated conclusive superiority.
CONCLUSIONS: To date, whereas no routine recommendations can be done, biotics supplemented IF have generally proven to be well-tolerated and safe in ensuring infants’ normal growth, paving the way for future IF alternatives for those infants who are not able to be (fully) breastfed. More RCTs, with adequate design and statistical power, are still needed to better clarify, if present, which benefits the supplementation of IF may confer to infants’ short and long-term outcomes.


KEY WORDS: Infant formula; Probiotics; Prebiotics; Human milk oligosaccharides; Synbiotics; Postbiotics

inizio pagina